此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma

2026年6月25日 更新者:Ou Bai, MD/PHD

Efficacy and Safety of Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma: a Single-center, Single-arm, Prospective Study

This is a single-center, single-arm, prospective study aimed at evaluating the efficacy and safety of orelabrutinib combined with an induction regimen followed by monotherapy maintenance in patients with MCD subtype diffuse large B-cell lymphoma (DLBCL). The primary endpoint is the 2-year progression-free survival (PFS) rate; secondary endpoints include overall response rate (ORR), complete response rate (CRR), overall survival (OS), and treatment-related adverse events (TRAEs). The study plans to enroll 66 patients.

研究概览

详细说明

This is a single-center, single-arm, prospective study aimed at evaluating the efficacy and safety of orelabrutinib combined with an induction regimen followed by monotherapy maintenance in patients with MCD subtype diffuse large B-cell lymphoma (DLBCL).

研究类型

介入性

注册 (估计的)

66

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:ou bai, MD/PHD
  • 电话号码:13039046656
  • 邮箱:oubai16@163.com

学习地点

    • Jilin
      • Changchun、Jilin、中国、130021
        • The First Bethune Hospital of Jilin University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Patients of any gender, aged ≥18 years;
  • Pathologically, NGS, and imaging confirmed diagnosis of MCD subtype DLBCL (including IP-LBCLs);
  • No prior treatment history;
  • Serum creatinine ≤2 times the upper limit of normal or eGFR ≥40 ml/min;
  • Bilirubin <1.5 times the upper limit of normal;
  • Understand and voluntarily sign a written informed consent form.

Exclusion Criteria:

  • Pregnant or lactating women and women of childbearing age who are unwilling to use contraception;
  • Patients with a history of stroke or bleeding within the past 6 months;
  • Patients requiring treatment with strong CYP3A inhibitors;
  • Patients with comorbid autoimmune deficiency diseases or active hepatitis virus infection;
  • Patients with a history of organ transplantation;
  • Patients with a history of or concurrent other malignant tumors.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Orelabrutinib Combined with chemotherapy followed by monotherapy in ND MCD subtype DLBCL

For MCD subtype DLBCL (including IP-LBCLs) that have undergone two cycles of induction therapy, combine orelabrutinib treatment starting from the third cycle.

For patients with poor prognostic factors (meeting one of the following: Ann Arbor stage III/IV; IPI score 3-5; aaIPI score 2-3; high-intermediate or high-risk group per MSKCC and/or IELSG criteria), continue with two additional cycles of orelabrutinib-combined induction therapy, followed by orelabrutinib monotherapy maintenance for 2 years or until disease progression or intolerable toxicity.

For patients without poor prognostic factors, administer orelabrutinib monotherapy maintenance for 1 year or until disease progression or intolerable toxicity.

R-CHOP Regimen Rituximab: 375 mg/m², Day 0 Cyclophosphamide: 750 mg/m², Day 1 Doxorubicin: 50 mg/m², Day 1 Vincristine: 1.4 mg/m², Day 1 (maximum single dose: 2 mg) Prednisone: 100 mg, Days 1-5 Orelabrutinib 150mg QD every 21 days per cycle in Induction therapy, 28 days/cycle during maintenance therapy
其他名称:
  • 利妥昔单抗
  • 环磷酰胺
  • 强的松
  • 阿霉素
  • 长春新碱
  • 奥布替尼
POLA-R-CHP+orelabrutinib Rituximab: 375 mg/m², Day 1 Vepoliximab: 1.8 mg/kg, Day 1 Cyclophosphamide: 750 mg/m², Day 1 Doxorubicin: 50 mg/m², Day 1 Prednisone: 100 mg, Days 1-5 orelabrutinib 150mg QD every 21 days per cycle in Induction therapy, 28 days/cycle during maintenance therapy
其他名称:
  • 利妥昔单抗
  • 环磷酰胺
  • 强的松
  • 阿霉素
  • 奥布替尼
  • Vepoliximab
R-miniCHOP Regimen Rituximab: 375 mg/m², Day 0 Cyclophosphamide: 400 mg/m², Day 1 Doxorubicin: 25 mg/m², Day 1 Vincristine: 1 mg, Day 1 Prednisone: 40 mg/m², Days 1-5 orelabrutinib 150mg QD every 21 days per cycle in Induction therapy, 28 days/cycle during maintenance therapy
其他名称:
  • 利妥昔单抗
  • 环磷酰胺
  • 强的松
  • 阿霉素
  • 长春新碱
  • 奥布替尼
Zuberitamab: 375 mg/m², Day 0 Cyclophosphamide: 400 mg/m², Day 1 Doxorubicin: 25 mg/m², Day 1 Vincristine: 1 mg, Day 1 Prednisone: 40 mg/m², Days 1-5 orelabrutinib 150mg QD every 21 days per cycle in Induction therapy, 28 days/cycle during maintenance therapy
其他名称:
  • 环磷酰胺
  • 强的松
  • 阿霉素
  • 长春新碱
  • Zuberitamab
POLA-Hi-CHP+orelabrutinib Zuberitamab: 375 mg/m², Day 1 Vepoliximab: 1.8 mg/kg, Day 1 Cyclophosphamide: 750 mg/m², Day 1 Doxorubicin: 50 mg/m², Day 1 Prednisone: 100 mg, Days 1-5 orelabrutinib 150mg QD every 21 days per cycle in Induction therapy, 28 days/cycle during maintenance therapy
其他名称:
  • 环磷酰胺
  • 强的松
  • 阿霉素
  • 奥布替尼
  • Vepoliximab
  • Zuberitamab
Hi-miniCHOP Regimen Zuberitamab: 375 mg/m², Day 0 Cyclophosphamide: 400 mg/m², Day 1 Doxorubicin: 25 mg/m², Day 1 Vincristine: 1 mg, Day 1 Prednisone: 40 mg/m², Days 1-5 orelabrutinib 150mg QD every 21 days per cycle in Induction therapy, 28 days/cycle during maintenance therapy
其他名称:
  • 环磷酰胺
  • 阿霉素
  • 长春新碱
  • 奥布替尼
  • Zuberitamab
  • Prednisone,
RMTO Regimen Rituximab: 375 mg/m², Day 1 Methotrexate: 3.5 g/m², Day 2 Thiotepa 30 mg/m² Day 4 Orelabrutinib: 150 mg, Days 1-21 every 21 days per cycle in Induction therapy, maintenance therapy 28 days/cycle
其他名称:
  • 利妥昔单抗
  • 甲氨蝶呤
  • 噻替哌
  • 奥布替尼
HiMTO Regimen Zuberitamab: 375 mg/m², Day 1 Methotrexate: 3.5 g/m², Day 2 Thiotepa 30 mg/m² Day 4 Orelabrutinib: 150 mg, Days 1-21 every 21 days per cycle in Induction therapy, maintenance therapy 28 days/cycle
其他名称:
  • 甲氨蝶呤
  • 噻替哌
  • 奥布替尼
  • Zuberitamab
Pola-R-miniCHP Regimen Polatuzumab vedotin: 1.8 mg/kg IV, Day 1 Rituximab: 375 mg/m² IV, Day 1 Cyclophosphamide: 400 mg/m² IV, Day 1 Doxorubicin: 25 mg/m² IV, Day 1 Prednisone: 40 mg/m² PO, Days 1-5 every 21 days per cycle in Induction therapy, maintenance therapy 28 days/cycle
其他名称:
  • 利妥昔单抗
  • 环磷酰胺
  • 强的松
  • 阿霉素
  • Polatuzumab vedotin
Pola-Hi-miniCHP Regimen (21-day cycle, up to 6 cycles) Polatuzumab vedotin: 1.8 mg/kg IV, Day 1 Zuberitamab: 375 mg/m² IV, Day 1 Cyclophosphamide: 400 mg/m² IV, Day 1 Doxorubicin: 25 mg/m² IV, Day 1 Prednisone: 40 mg/m² PO, Days 1-5 every 21 days per cycle in Induction therapy, maintenance therapy 28 days/cycle
其他名称:
  • 环磷酰胺
  • 强的松
  • 阿霉素
  • 奥布替尼
  • Zuberitamab
  • Polatuzumab vedotin

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
2year PFS
大体时间:From the start of treatment up to 2 years
The percentage of subjects who had not experienced disease progression or all-cause death at 24 months from first dose, relative to the total enrolled population.
From the start of treatment up to 2 years

次要结果测量

结果测量
措施说明
大体时间
ORR
大体时间:From the start of treatment up to 2 years
The proportion of patients who achieved a PR or better response at the end of therapy
From the start of treatment up to 2 years
CRR
大体时间:From the start of treatment up to 2 years
Proportion of patients achieving CR at the end of treatment
From the start of treatment up to 2 years
OS
大体时间:From the start of treatment up to 2 years
Time from treatment initiation to death from any cause
From the start of treatment up to 2 years
AEs
大体时间:From the start of treatment up to 2 years
All adverse medical events that occurred after the initiation of treatment
From the start of treatment up to 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月16日

初级完成 (估计的)

2029年12月31日

研究完成 (估计的)

2031年12月31日

研究注册日期

首次提交

2026年6月22日

首先提交符合 QC 标准的

2026年6月25日

首次发布 (实际的)

2026年7月1日

研究记录更新

最后更新发布 (实际的)

2026年7月1日

上次提交的符合 QC 标准的更新

2026年6月25日

最后验证

2026年6月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅